146 related articles for article (PubMed ID: 22361784)
1. The relationship between symptomatology and treatment selection in metastatic castrate-resistant prostate cancer.
Small EJ; Penson DF; Sartor O
Clin Adv Hematol Oncol; 2011 Jul; 9(7 Suppl 13):1-15. PubMed ID: 22361784
[TBL] [Abstract][Full Text] [Related]
2. New therapies for castration-resistant prostate cancer: efficacy and safety.
Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
[TBL] [Abstract][Full Text] [Related]
3. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
4. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
6. Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer.
George DJ; Kantoff PW; Lin DW
Clin Adv Hematol Oncol; 2011 Jun; 9(6):1-11; discussion 11-5. PubMed ID: 21941983
[TBL] [Abstract][Full Text] [Related]
7. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
[TBL] [Abstract][Full Text] [Related]
8. New developments in castrate-resistant prostate cancer.
Shore N; Mason M; de Reijke TM
BJU Int; 2012 Jun; 109 Suppl 6():22-32. PubMed ID: 22672122
[TBL] [Abstract][Full Text] [Related]
9. Current and emerging treatments in the management of castration-resistant prostate cancer.
Shapiro D; Tareen B
Expert Rev Anticancer Ther; 2012 Jul; 12(7):951-64. PubMed ID: 22845410
[TBL] [Abstract][Full Text] [Related]
10. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
11. New and emerging treatments for advanced prostate cancer.
George DJ; Kantoff PW; Lin DW
Clin Adv Hematol Oncol; 2011 Jun; 9(6 Suppl 12):1-15. PubMed ID: 22361744
[TBL] [Abstract][Full Text] [Related]
12. New and emerging agents for the treatment of castration-resistant prostate cancer.
Higano CS; Crawford ED
Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657
[TBL] [Abstract][Full Text] [Related]
13. Novel agents for the management of castration-resistant prostate cancer.
Haddad H; Garcia JA
Curr Opin Urol; 2012 May; 22(3):175-82. PubMed ID: 22472509
[TBL] [Abstract][Full Text] [Related]
14. Abiraterone acetate for the treatment of prostate cancer.
Ryan CJ; Cheng ML
Expert Opin Pharmacother; 2013 Jan; 14(1):91-6. PubMed ID: 23199349
[TBL] [Abstract][Full Text] [Related]
15. Updates on therapeutic targets and agents in castration-resistant prostate cancer.
Bishr M; Lattouf JB; Gannon PO; Saad F
Minerva Urol Nefrol; 2011 Jun; 63(2):131-43. PubMed ID: 21623331
[TBL] [Abstract][Full Text] [Related]
16. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
Pili R; Häggman M; Stadler WM; Gingrich JR; Assikis VJ; Björk A; Nordle O; Forsberg G; Carducci MA; Armstrong AJ
J Clin Oncol; 2011 Oct; 29(30):4022-8. PubMed ID: 21931019
[TBL] [Abstract][Full Text] [Related]
17. Abiraterone acetate in castration-resistant prostate cancer.
Iacovelli R; Palazzo A; Procopio G; Gazzaniga P; Cortesi E
Anticancer Drugs; 2012 Mar; 23(3):247-54. PubMed ID: 22123334
[TBL] [Abstract][Full Text] [Related]
18. Serum tri- and tetra-antennary N-glycan is a potential predictive biomarker for castration-resistant prostate cancer.
Ishibashi Y; Tobisawa Y; Hatakeyama S; Ohashi T; Tanaka M; Narita S; Koie T; Habuchi T; Nishimura S; Ohyama C; Yoneyama T
Prostate; 2014 Nov; 74(15):1521-9. PubMed ID: 25154914
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in second-line treatment of castration-resistant prostate cancer.
Ong M; Winquist E
Curr Opin Support Palliat Care; 2011 Sep; 5(3):199-205. PubMed ID: 21734586
[TBL] [Abstract][Full Text] [Related]
20. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF
BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
